We show here that the combination therapy of the CDK4/6 inhibitor Palbociclib and the PARP inhibitor Talazoparib has synergistic anticancer effects on RB-positive urothelial carcinoma cells in vitro and in xenograft models. The gene discussed is CDK4; the disease is urothelial carcinoma.